NEW YORK, July 22, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on Receptos,
Inc. (NASDAQ: RCPT). Select highlights from the internally released
reports are being made available to the general public (included
below), with access to the entirety of the research available to
new members.
Today, membership is open to readers on a complementary basis at
the following URL: http://www.aciassociation.com/?c=RCPT
Highlights from our RCPT Report include:
- Positive Results for the Maintenance period of
Clinical Trial - On April 16,
2015, Receptos, Inc. reported positive results for the
maintenance period of TOUCHSTONE, the Phase 2 trial of ozanimod
(formerly RPC1063) in ulcerative colitis (UC). The results showed
that the study has met all efficacy endpoints with statistical
significance in patients on the 1 mg dose of ozanimod after 32
weeks of treatment.
- Assessment Of Ozanimod Versus Placebo In Details
- The aforesaid study evaluated the efficacy, safety and
tolerability of two orally administered doses (0.5 mg and 1 mg) of
ozanimod versus placebo. This randomized, double-blind,
placebo-controlled trial was conducted in 199 patients with
moderately-to-severely active UC across 57 sites in 13 countries.
Receptos informed that the trial met its primary efficacy and all
secondary endpoints for patients with 1 mg dose after 8 weeks of
treatment in the induction period. The 103 patients, who achieved
clinical response in the maintenance period at the eight week,
continued with treatment for 24 more weeks. At week 32, all
secondary end-points were positive and statistically significant
for the 1 mg dose. The secondary endpoints at week 32 included
clinical response, change in the industry standard Mayo score and
mucosal improvement on endoscopy. Further, the proportion of
patients in clinical remission at week 32 was statistically
significant in favor of both the 1 mg group and the 0.5 mg group (p
< 0.05) compared to placebo.
- Plans to start Phase 3 Trial - In 2015,
the Company plans to go ahead with a Phase 3 program to confirm the
findings of Phase 2. The phase 3 trial would be conducted in
patients with moderately-to-severely active UC. Furthermore, these
results continue to suggest the potential for ozanimod to be used
in the treatment of a related inflammatory bowel disease called
Crohn's. The Company stated that it would be initiating a
Phase 2 study of ozanimod for the treatment of Crohn's disease in
2015.
- Management's Comments - President
and Chief Executive Officer of Receptos, Faheem Hasnain said, "The positive results of
the maintenance period of the TOUCHSTONE study exceeded our
expectations with respect to the potential for long term clinical
benefit of ozanimod in ulcerative colitis." He added, "The
consistency of the efficacy data across the various endpoints for
the high dose, combined with the favorable safety profile, gives us
continued confidence to advance the development of ozanimod in
inflammatory bowel disease."
To find out how this influences our rating on Receptos, Inc.
read the full report in its entirety here:
http://www.aciassociation.com/?c=RCPT
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the CFA®
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com